VKTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Viking Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$25.05−0.12 (-0.48%)
Close on Oct 19, 2026
- Market cap
- $2.91B
- P/E (TTM)
- –
- Dividend yield
- –
Dividends
Viking Therapeutics has not reported a dividend
No dividend per share appears in Viking Therapeutics's annual filings since fiscal 2013.